



## The 2021 Scheele Symposium

November 11, Stockholm and online

# Targeted protein degradation

– an emerging therapeutic approach in drug discovery

Professor Craig Crews, Yale University, New Haven, USA



Welcome to the Scheele Symposium in honour of the 2021 Scheele award laureate, **Professor Craig Crews**. The symposium focuses on various aspects of his research, including insights into the PROTAC-technology. Take this opportunity to listen to some of the world's top scientists in the area of targeted protein degradation.

### Program

**Moderator:** Dr Malin Lemurell, AstraZeneca, Sweden

09.30 **Introduction and welcome**

Dr. Märit Johansson, Chairman,  
Swedish Pharmaceutical Society

09.45 **The yin and yang of the ubiquitin proteasome system in drug discovery and development**

Prof. Mikael Elofsson, Umeå University, Sweden

10.05 **Protein degradation in multiple myeloma and the mechanism-of-action for the immunomodulatory imide drugs (IMiDs)**

Prof. Benjamin Ebert, Harvard University, USA

10.30 Break

11.00 **Discovery of molecular glue degraders at scale**

Dr. Cristina Mayor-Ruiz, Institute for Research in Biomedicine, Spain

11.25 **How PROTACs work: Molecular recognition and design principles**

Prof. Alessio Ciulli, University of Dundee, Scotland

11.50 Speed talks – Young scientists

12.30 Lunch

13.45 **Pharmacodynamic responses PROTAC**

Dr. Alina Mares, GSK, UK

14.10 **Perspective and learnings of the PROTAC modality from Cardiovascular, Renal and Metabolism disease area**

Dr Johan Johansson, AstraZeneca, Sweden

14.35 **Swedish academia-industry perspective on the PROTAC technology in drug development**

Prof. Per Arvidsson, Scilifelab, Sweden

15.00 Break

15.30 **Scheele award lecture: Proteasome inhibitors and PROTACs – Clinical development**

Prof. Craig Crews, Yale University, USA

16.00 **Scheele award ceremony**

Dr. Märit Johansson, Chairman,  
Swedish Pharmaceutical Society  
Matilda Ernkrans, Minister of higher education,  
Sweden

16.15 **Panel debate – Challenges and opportunities with targeted protein degradation for therapeutic intervention**

Prof. Craig Crews and speakers from above.

**Moderator:** Peter Sjö, DnDi, Switzerland

17.00 End

 [www.apotekarsocieteten.se](http://www.apotekarsocieteten.se)